APG-1387 in combination with TRAIL was shown to selectively target CSCs and down-regulate CSC properties of HCC in HCCLM3 cells, which is consistent with the previous findings in glioblastoma and nasopharyngeal carcinoma (Wu et al., 2013; Tchoghandjian et al., 2014). The gene discussed is TNFSF10; the disease is nasopharyngeal carcinoma.